ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Computational Clinical Scientist at Revolution Medicines - ApplyBlast

Computational Clinical Scientist

Revolution Medicines

2 months ago

3.5 on Glassdoor

Redwood City, California, United States

Onsite

Full Time

Junior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Computational Clinical Scientist will work within Revolution Medicines' Translational Medicine group to analyze and interpret molecular and clinical data, focusing on genomic, protein, and targeted assay integration to identify and validate predictive biomarkers for oncology drug development. The role collaborates with bioinformaticians, biomarker scientists, pre‑clinical teams, and external partners to deliver biomarker analyses that support trial design, regulatory documentation, and patient selection.

Responsibilities

Integrate multiple data sources to identify and validate biomarkers
Support biomarker-related trial design and regulatory documentation
Collaborate with preclinical bioinformaticians to design and interpret experiments

Skills

Qualifications

M.S. in BioinformaticsPh.D. in Bioinformatics

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.